Seirafian Shiva, Haghdarsaheli Yalda, Mortazavi Mojgan, Hosseini Mohsen, Moeinzadeh Firouzeh
Department of Internal Medicine and Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2014 Dec 31;3:261. doi: 10.4103/2277-9175.148234. eCollection 2014.
The risk of cardiovascular disease in dialysis patients is higher than the general population. Vitamin D receptors exist in myocardium inhibit cardiac hypertrophy. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a neurohormone secreted by the heart in response to ventricular mass increase. This study aimed to evaluate the effect of oral vitamin D on serum level of pro-B-type natriuretic peptide (pro-BNP) in peritoneal dialysis patients.
In a randomized clinical trial, 84 peritoneal dialysis patients (49 males and 35 females) were randomly divided into two groups. The intervention group received 50000 units oral vitamin D per week, for 12 weeks if 25-hydroxy-vitamin D level was <10 ng/ml and for 8 weeks if it was between 10 ng/ml and 30 ng/ml. The control group received placebo. Parathyroid hormone, calcium, phosphor, 25-hydroxy-vitamin D, albumin and NT-pro-BNP were evaluated before and after the study.
The mean serum level of pro-BNP in patients receiving vitamin D and placebo group before the study was 875 pg/ml and 793 pg/ml, respectively. There was 895.9 pg/ml in the intervention group and 736.7 pg/ml in the control group (P = 0.7). Mean serum level of 25(OH) D in patients receiving oral vitamin D and placebo group before the study was 16.9 ng/ml and 31.9 ng/ml, respectively. There was 28.9 ng/ml in the intervention group and 12.9 ng/ml in the control group (P = 0.001). There were no significant differences regarding other indices (Alb, P, Ca, intact parathyroid hormone) between two groups.
Vitamin D did not significantly change the serum level of pro-BNP in peritoneal dialysis patients.
透析患者发生心血管疾病的风险高于普通人群。心肌中存在维生素D受体，可抑制心肌肥大。N末端B型利钠肽原（NT-pro-BNP）是心脏在心室质量增加时分泌的一种神经激素。本研究旨在评估口服维生素D对腹膜透析患者血清B型利钠肽原（pro-BNP）水平的影响。
在一项随机临床试验中，84例腹膜透析患者（49例男性和35例女性）被随机分为两组。干预组每周口服50000单位维生素D，若25-羟维生素D水平<10 ng/ml，则服用12周；若在10 ng/ml至30 ng/ml之间，则服用8周。对照组服用安慰剂。在研究前后评估甲状旁腺激素、钙、磷、25-羟维生素D、白蛋白和NT-pro-BNP。
研究前接受维生素D组和安慰剂组患者的血清pro-BNP平均水平分别为875 pg/ml和793 pg/ml。干预组为895.9 pg/ml，对照组为736.7 pg/ml（P = 0.7）。研究前接受口服维生素D组和安慰剂组患者的血清25(OH)D平均水平分别为16.9 ng/ml和31.9 ng/ml。干预组为28.9 ng/ml，对照组为12.9 ng/ml（P = 0.001）。两组在其他指标（白蛋白、磷、钙、完整甲状旁腺激素）方面无显著差异。
维生素D并未显著改变腹膜透析患者的血清pro-BNP水平。
